Zepbound (Tirzepatide) Diarrhea Severity Grading Rubric: Causes, Management, and When to Call Your Doctor
At a glance
- Diarrhea rate / 19% (5 mg), 21% (10 mg), 23% (15 mg) vs 8% placebo [1]
- Severe GI reaction rate / 1.7%, 2.5% and 3.1% vs 1% placebo [1]
- Stopped treatment for GI side effects / 1.9%, 3.3% and 4.3% vs 0.5% placebo [1]
- Timing / most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]
- Label kidney warning / acute kidney injury from volume depletion; renal function to be monitored in patients reporting reactions that could cause it [1]
- When a maintenance dose is not tolerated / the label says consider a lower maintenance dose [1]
- Not recommended in / severe gastroparesis [1]
Does the Zepbound label have a diarrhea severity scale?
No. What the label reports is how many people had any gastrointestinal reaction, how many had a severe one, and how many stopped treatment [1]:
- Any gastrointestinal adverse reaction: 56% at every Zepbound dose, versus 30% on placebo [1].
- Severe gastrointestinal adverse reactions: 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, versus 1% on placebo [1].
- Discontinuation for a gastrointestinal reason: 1.9% at 5 mg, 3.3% at 10 mg and 4.3% at 15 mg, versus 0.5% on placebo [1].
The label reports these outcomes separately; none provides a diarrhea severity grade or stool-count cutoff.
Diarrhea rates at each Zepbound dose
The label pools two placebo-controlled weight-management trials: 2,519 adults treated with Zepbound for up to 72 weeks, mean age 47, mean BMI 37.4, and 25% with type 2 diabetes [1].
| Zepbound dose | Diarrhea |
|---|---|
| Placebo | 8% |
| 5 mg | 19% |
| 10 mg | 21% |
| 15 mg | 23% |
The label's diarrhea category includes frequent bowel movements [1]. Nausea was reported more often than diarrhea at every dose — 25%, 29% and 28% versus 8% on placebo [1].
When during treatment diarrhea tends to appear
Most nausea, vomiting and diarrhea occurred during dose escalation and decreased over time [1]. The escalation schedule is written with that in mind: 2.5 mg once weekly for 4 weeks, then 5 mg, then increases of 2.5 mg no sooner than every 4 weeks, a sequence the label specifies to reduce the risk of gastrointestinal adverse reactions [1]. The 2.5 mg dose is for initiation only and is not approved as a maintenance dose; maintenance for weight reduction is 5, 10 or 15 mg once weekly [1].
Separately, the label notes that tirzepatide delays gastric emptying, that this delay is largest after the first dose and that it diminishes over time [1].
What the label ties to diarrhea
Dehydration and kidney injury. The label describes postmarketing reports of acute kidney injury, in some cases requiring hemodialysis, mostly in patients who had gastrointestinal reactions leading to dehydration such as nausea, vomiting or diarrhea. It says to monitor renal function in patients reporting reactions that could lead to volume depletion, especially during initiation and dose escalation [1].
Abdominal pain and pancreatitis. The label says acute pancreatitis may show as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. It says to discontinue Zepbound if pancreatitis is suspected [1].
Severe gastroparesis. Zepbound is not recommended in patients with severe gastroparesis [1].
Fluids
WHO and UNICEF describe oral rehydration salts, a glucose-electrolyte solution, as a way to treat dehydration from diarrhea, and note that extra fluids at home can help prevent it [2].
Frequently asked questions
How long does Zepbound diarrhea last?
Which Zepbound dose causes the most diarrhea?
Can Zepbound diarrhea cause kidney problems?
What does the label say about lowering a dose?
What do WHO and UNICEF say about oral rehydration salts?
References
- U.S. National Library of Medicine, DailyMed. Zepbound injection (tirzepatide) prescribing information. Zepbound injection (tirzepatide) label
- Oral rehydration salts. Oral rehydration salts